A Phase 1/2, Dose-escalation, Open-label, Non-comparative Study of Nivolumab or Nivolumab in Combination with Ipilimumab in Advanced Hepatocellular Carcinoma Subjects with or without Chronic Viral Hepatitis; and a Randomized, Open-label Study of Nivolumab vs Sorafenib in Advanced Hepatocellular Carcinoma Subjects who are Naive to Systemic Therapy
An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a
“CC#139511: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma
Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies
Mutational Analysis and Serum Proteomic characterization of patient samples: prelude to the MMRC sponsored trial of the multi targeted kinase inhibitor PKC412
A Phase I Trial of MK-3475 in Combination with Lenalidomide and Dexamethasone in Subjects with Multiple Myeloma
